AngioLab, Inc.
Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.
251280 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 테크노3로 65, 대전광역시
- Website:
- https://angiolab.co.kr/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
AngioLab, Inc. is a biotechnology company established in 1999 that specializes in the research and development of therapeutics based on angiogenesis inhibition. The company develops pharmaceuticals and health functional foods designed to treat a variety of angiogenesis-related diseases. Its core technology focuses on the discovery and application of anti-angiogenic and matrix metalloproteinase (MMP) inhibitors. AngioLab manages a pipeline of drug candidates, advancing them through clinical trials to create novel treatments for conditions driven by abnormal blood vessel formation.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for AngioLab, Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all AngioLab, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for AngioLab, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
